Apimeds Pharmaceuticals US (APUS) Operating Expenses (2024 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Operating Expenses for 3 consecutive years, with $6.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 135.7% year-over-year to $6.3 million; the trailing twelve-month figure through Jun 2026 stood at $17.8 million (up 394.66% YoY), and the FY2025 full-year result was $11.9 million, up 834.25% from the prior year.
• Operating Expenses slipped to $6.3 million in Q2 2026 per APUS's latest filing, from $7.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $7.0 million in Q4 2025 and bottomed at $271726.0 in Q1 2024.
• Historically, Operating Expenses has averaged $2.2 million across 3 years, with a median of $427757.0 in 2024.
• The widest YoY moves for Operating Expenses: up 2454.32% in 2025, down 34.09% in 2025.
• Over 3 years, Operating Expenses stood at $275613.0 in 2024, then soared by 2454.32% to $7.0 million in 2025, then dropped by 10.81% to $6.3 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $6.3 million, $7.0 million, and $1.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.